Design of Peptide-Based Nanovaccines Targeting Leading Antigens From Gynecological Cancers to Induce HLA-A2.1 Restricted CD8+ T Cell Responses
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Design of Peptide-Based Nanovaccines Targeting Leading Antigens From Gynecological Cancers to Induce HLA-A2.1 Restricted CD8+ T Cell Responses
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2018-12-21
DOI
10.3389/fimmu.2018.02968
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mechanisms of resistance to immune checkpoint inhibitors
- (2018) Russell W Jenkins et al. BRITISH JOURNAL OF CANCER
- Expression and clinical significance of survivin in ovarian cancer: A meta-analysis
- (2018) Xiaoyan He et al. PLoS One
- Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer
- (2017) Woosung Chung et al. Nature Communications
- Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer
- (2017) et al. JAMA Oncology
- Survivin: a unique target for tumor therapy
- (2016) Himani Garg et al. Cancer Cell International
- Survivin Overexpression Is Associated with Aggressive Clinicopathological Features in Cervical Carcinoma: A Meta-Analysis
- (2016) Ke-yan Cheng et al. PLoS One
- A Model to Study the Impact of Polymorphism Driven Liver-Stage Immune Evasion by Malaria Parasites, to Help Design Effective Cross-Reactive Vaccines
- (2016) Kirsty L. Wilson et al. Frontiers in Microbiology
- Polymorphism in liver-stage malaria vaccine candidate proteins: immune evasion and implications for vaccine design
- (2015) Katie L. Flanagan et al. Expert Review of Vaccines
- Feasibility of Cancer Immunotherapy with WT1 Peptide Vaccination for Solid and Hematological Malignancies in Children
- (2015) Akihisa Sawada et al. PEDIATRIC BLOOD & CANCER
- Montanide, Poly I:C and nanoparticle based vaccines promote differential suppressor and effector cell expansion: a study of induction of CD8 T cells to a minimal Plasmodium berghei epitope
- (2015) Kirsty L. Wilson et al. Frontiers in Microbiology
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Identification of promiscuous HPV16-derived T helper cell epitopes for therapeutic HPV vaccine design
- (2014) Agnieszka K. Grabowska et al. INTERNATIONAL JOURNAL OF CANCER
- Comprehensive Analysis of HLA-DR- and HLA-DP4-Restricted CD4+ T Cell Response Specific for the Tumor-Shared Antigen Survivin in Healthy Donors and Cancer Patients
- (2014) X.-F. Wang et al. JOURNAL OF IMMUNOLOGY
- Ovarian cancer
- (2014) Gordon C Jayson et al. LANCET
- Wilms’ Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses
- (2013) Benjamin Uttenthal et al. BRITISH JOURNAL OF HAEMATOLOGY
- Survivin Status Affects Prognosis and Chemosensitivity in Epithelial Ovarian Cancer
- (2013) Lifeng Chen et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Differential Uptake of Nanoparticles and Microparticles by Pulmonary APC Subsets Induces Discrete Immunological Imprints
- (2013) C. L. Hardy et al. JOURNAL OF IMMUNOLOGY
- The signalling imprints of nanoparticle uptake by bone marrow derived dendritic cells
- (2013) Tanya De L. Karlson et al. METHODS
- Methods of effective conjugation of antigens to nanoparticles as non-inflammatory vaccine carriers
- (2013) Sue D. Xiang et al. METHODS
- Role of T Cell Receptor Affinity in the Efficacy and Specificity of Adoptive T Cell Therapies
- (2013) Jennifer D. Stone et al. Frontiers in Immunology
- Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma
- (2012) Jürgen C. Becker et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Functional differences between low- and high-affinity CD8+T cells in the tumor environment
- (2012) Rinke Bos et al. OncoImmunology
- Detection of survivin expression in cervical cancer cells using molecular beacon imaging: new strategy for the diagnosis of cervical cancer
- (2011) Yan Xue et al. European Journal of Obstetrics & Gynecology and Reproductive Biology
- Promiscuous survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients
- (2011) Melanie Widenmeyer et al. INTERNATIONAL JOURNAL OF CANCER
- Sperm Protein 17: Clinical Relevance of a Cancer/Testis Antigen, from Contraception to Cancer Immunotherapy, and Beyond
- (2011) Maurizio Chiriva-Internati INTERNATIONAL REVIEWS OF IMMUNOLOGY
- WT1 peptide vaccination following allogeneic stem cell transplantation in pediatric leukemic patients with high risk for relapse: successful maintenance of durable remission
- (2011) Y Hashii et al. LEUKEMIA
- Antitumor cytotoxic T-cell response induced by a survivin peptide mimic
- (2010) Michael J. Ciesielski et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer
- (2010) Akihiro Miyazaki et al. CANCER SCIENCE
- Potential Target Antigens for a Universal Vaccine in Epithelial Ovarian Cancer
- (2010) Renee Vermeij et al. Clinical & Developmental Immunology
- Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies
- (2010) K. Rezvani et al. HAEMATOLOGICA
- WT1 (Wilms' Tumor Gene 1): Biology and Cancer Immunotherapy
- (2010) H. Sugiyama JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Perspectives for Preventive and Therapeutic HPV Vaccines
- (2010) Ken Lin et al. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
- The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
- (2009) M. A. Cheever et al. CLINICAL CANCER RESEARCH
- Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine
- (2008) M. J.P. Welters et al. CLINICAL CANCER RESEARCH
- Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity
- (2008) G. G. Kenter et al. CLINICAL CANCER RESEARCH
- Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme
- (2008) Shuichi Izumoto et al. JOURNAL OF NEUROSURGERY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started